SHARPIN regulates uropod detachment in migrating lymphocytes

Pouwels, Jeroen

2013


http://hdl.handle.net/10138/165430
https://doi.org/10.1016/j.celrep.2013.10.011

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
SHARPIN Regulates Uropod Detachment in Migrating Lymphocytes

Jeroen Pouwels,1,2,10 Nicola De Franceschi,1,2,10 Pia Rantakari,3 Kaisa Auvinen,3,8 Marika Karikoski,3 Elina Mattila,1 Christopher Potter,4 John P. Sundberg,4 Nancy Hogg,5 Carl G. Gahmberg,6 Marko Salmi,3,7,8,10 and Johanna Ivaska1,2,9,10,1*

1Medical Biotechnology, VTT Technical Research Centre of Finland, 20521 Turku, Finland
2Turku Centre for Biotechnology, University of Turku, 20521 Turku, Finland
3MediCity Research Laboratory, University of Turku, 20521 Turku, Finland
4The Jackson Laboratory, Bar Harbor, ME 04609, USA
5Leukocyte Adhesion Laboratory, Cancer Research UK London Research Institute, London WC2A 3LY, UK
6Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, FI-00014 Helsinki, Finland
7Department of Medical Biochemistry and Genetics, University of Turku, 20521 Turku, Finland
8Inflammatory Mechanisms Unit, National Institute for Health and Welfare, 20521 Turku, Finland
9Department of Biochemistry and Food Chemistry, University of Turku, 20521 Turku, Finland
10These authors contributed equally to this work
*Correspondence: johanna.ivaska@utu.fi

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

SUMMARY

SHARPIN-deficient mice display a multiorgan chronic inflammatory phenotype suggestive of altered leukocyte migration. We therefore studied the role of SHARPIN in lymphocyte adhesion, polarization, and migration. We found that SHARPIN localizes to the trailing edges (uropods) of both mouse and human chemokine-activated lymphocytes migrating on intercellular adhesion molecule-1 (ICAM-1), which is one of the major endothelial ligands for migrating leukocytes. SHARPIN-deficient cells adhere better to ICAM-1 and show highly elongated tails when migrating. The increased tail lifetime in SHARPIN-deficient lymphocytes decreases the migration velocity. The adhesion, migration, and uropod defects in SHARPIN-deficient lymphocytes were rescued by reintroducing SHARPIN into the cells. Mechanistically, we show that SHARPIN interacts directly with lymphocyte-function-associated antigen-1 (LFA-1), a leukocyte counterreceptor for ICAM-1, and inhibits the expression of intermediate and high-affinity forms of LFA-1. Thus, SHARPIN controls lymphocyte migration by endogenously maintaining LFA-1 inactive to allow adjustable detachment of the uropods in polarized cells.

INTRODUCTION

SHARPIN is a widely expressed cytosolic protein that, together with HOIL-1L interacting protein and HOIL-1L, forms the linear ubiquitin chain assembly complex (LUBAC) (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011). The ternary LUBAC complex catalyzes the formation of linear polyubiquitin chains, which regulate cell signaling, most notably the canonical nuclear factor (NF)-κB activation in response to stimuli like tumor necrosis factor (TNF).

A spontaneous SHARPIN-null mutation in Sharpincpdm mice manifests with a progressive multiorgan inflammatory phenotype (HogenEsch et al., 1993; Seymour et al., 2007). The most prominent feature in these mice is chronic proliferative dermatitis resembling psoriasis, but the mice also display leukocytosis, inflammation in many other organs (gastrointestinal track, liver, etc.), splenomegaly, abnormal development of Peyer’s patches, hypogammaglobulinemia, and defective Th1 cytokine production. The complex Sharpincpdm phenotype is partially linked to signaling and cytokine defects. Thus, the skin inflammation can be reversed by crossing Sharpincpdm mice with TNF-deficient mice (Gerlach et al., 2011). This is thought to be due to elimination of the increased LUBAC-dependent cell-death sensitivity of Sharpincpdm keratinocytes upon TNF triggering and subsequent alleviation of secondary inflammatory response. Sharpincpdm mice also have decreased secretion of proinflammatory cytokines (e.g., interferon-γ, interleukin [IL]-6, and IL-12) and increased secretion of Th2-type cytokines (IL-5; Renninger et al., 2010; Wang et al., 2012; Zak et al., 2011). However, the noncutaneous lymphoid aberrations are not affected by TNF elimination (Gerlach et al., 2011), mice deficient for HOIL-1 (another LUBAC component) do not appear to display any overt inflammatory phenotype (Tokunaga et al., 2009), and pharmacological inhibition of NF-κB signaling only partially alleviates the skin inflammation (Liang et al., 2011). Moreover, although blockade of IL-5 virtually eliminates eosinophils from Sharpincpdm mice, it does not affect the inflammation phenotype (Renninger et al., 2010). It is therefore tempting to speculate...
Figure 1. SHARPIN Regulates Uropod Detachment in Migrating Lymphocytes

(A) CXCL12-stimulated, wild-type, and Sharpin-deficient (Sharpcpdm) mouse splenocytes migrating on recombinant mouse ICAM-1 (5 μg/ml) immunostained for SHARPIN and CD44. Representative micrographs and quantitation of mean fluorescence intensities (MFI) along the cell axis (mean ± SEM [SEM in gray color]; n > 10 cells/staining; statistical comparisons between the 20 first frontal and 20 last posterior measurement points) are shown. The scale bars represent 10 μm.

(B) Adhesion to ICAM-1.

(C) Cell area.

(D) 0.5 μg/ml ICAM-1, 5 μg/ml ICAM-1, 50 μg/ml ICAM-1.

(E) Spleocyte migration (pathlength).

(F) % cells with extended tail.

(G) Polarity index.

(legend continued on next page)
that other, non-LUBAC-dependent functions of SHARPIN contribute to the dysregulated leukocyte accumulation seen in Sharpincpdm mice.

Chemokine-triggered leukocyte migration on endothelial cells is one crucial step during the leukocyte traffic into sites of inflammation (Ley et al., 2007; Vestweber, 2012). Given that SHARPIN has previously been reported to inhibit β1-integrins in cancer cells (Rantala et al., 2011), we asked whether SHARPIN could regulate leukocyte locomotion in inflammation. Here, we observed that SHARPIN strongly localizes to the trailing edges (called uropods in leukocytes) of migrating lymphocytes and controls uropod detachment and cell locomotion. In migrating lymphocytes, the leading edge and the midcell zone are thought to display active lymphocyte-function-associated antigen-1 (LFA-1, a heterodimeric αLβ2-integrin expressed on practically all leukocytes) capable of binding to intercellular adhesion molecule-1 (ICAM-1) and other ligands. Uropods, in contrast, express inactive LFA-1, which facilitates cellular detachment (Morin et al., 2008; Smith et al., 2005; Stanley et al., 2008). However, the mechanisms of uropodal LFA-1 deactivation have remained unknown. We now show that SHARPIN regulates lymphocyte polarity by directly interacting and deactivating LFA-1. Thus, our data reveal SHARPIN as a regulator of uropod detachment, which is the final checkpoint in leukocyte extravasation, and suggest a mechanism that dynamically controls deactivation of leukocyte integrins.

RESULTS

Impaired Uropod Detachment in SHARPIN-Deficient Lymphocytes

SHARPIN-deficient Sharpincpdm mice manifest with aberrant leukocyte infiltrations in many organs, and therefore, we studied whether SHARPIN would play a role in leukocyte locomotion. We found that endogenous SHARPIN is preferentially localized to the detached uropods, together with an established uropod marker CD44, in chemokine C-C motif ligand 12 (CXCL12)–activated wild-type splenocytes migrating on recombinitant mouse ICAM-1 (Figure 1A). Sharpincpdm splenocytes, which, as expected, lacked anti-mouse SHARPIN antibody reactivity, were flatter and displayed a loss of distinctive uropod structures, showing instead elongated trailing edges adherent to the substrate.

SHARPIN-deficient splenocytes and thymocytes adhered to and spread on ICAM-1 significantly better than wild-type cells (Figures 1B and 1C). Furthermore, lymphocyte migration on ICAM-1 was regulated by SHARPIN in a substrate-concentration-dependent manner (Figure 1D). When low levels of ICAM-1 substrate (0.5–5 μg/ml) were used, CXCL12-stimulated Sharpincpdm lymphocytes migrated significantly faster than wild-type cells. However, at a high ICAM-1 concentration (50 μg/ml), SHARPIN-deficient lymphocytes migrated much slower than the wild-type cells. Purified CD4+ T cells from Sharpincpdm mice also migrated faster on low ICAM-1 concentration and slower on high ICAM-1 concentration than purified wild-type CD4+ cells (Figure 1E; Movie S1). Sharpincpdm cells migrating on high ICAM-1 concentration had more extended tails than wild-type cells and showed an abnormally strongly polarized morphology (Figure 1F). Moreover, the uropod/tail lifetime was significantly longer for lymphocytes lacking SHARPIN, and consequently, the SHARPIN-deficient cells showed impaired detachment from the matrix (Figure 1F; Movie S2). Wild-type cells migrating on high ICAM-1 concentration (50 μg/ml) showed preferential localization of SHARPIN and CD44 to uropods and phalloidin staining revealed typical cortical F-actin enriched in the uropods, whereas talin (an integrin activator normally polarized to the cell front [Gómez-Mouton et al., 2001]) accumulated at the leading edges (Figure 1G). In Sharpincpdm cells, in contrast, CD44 and talin both distributed more evenly throughout the cells, and the strongly elongated tails were positive for filamentous actin throughout the tails.

Lymphocytes bind to ICAM-1 mainly via LFA-1 (Hogg et al., 2011). Integrin-mediated cell migration is dependent on receptor expression levels, receptor activity, and ligand density (following a bell-shaped curve), and detachment of trailing edges of cells requires disassembly of integrin-containing adhesions (Constantin et al., 2000; Franco et al., 2004; Palecek et al., 1997). Therefore, the increased migration speed on low ICAM-1 concentration and the elongated tails on high ICAM-1 concentration in Sharpincpdm lymphocytes could be indicative of higher LFA-1 expression levels or activity. We found that αLβ2 (LFA-1) integrin was expressed on practically all thymocytes and splenocytes (92%–95%; n = 7–8 mice/group) of both wild-type and Sharpincpdm mice, and the levels were comparable (thymocytes and CD4+ splenocytes) or slightly lower (total splenocytes) on Sharpincpdm cells (Figures 2A and 2B). The expression of other integrins (αM/CD11b, αX/CD11c, and α4/CD49d) and the numbers of CD4+ and CD8+ T cells, B220+ B cells, CD4+CD25+FoxP3+ T regulatory cells, and cells expressing chemokine receptors (CXCR4, CCR7, and CCR9) and activation markers (CD25 and L-selectin) were also similar in spleen and thymus of wild-type and Sharpincpdm mice, with the exception of minor changes in the numbers of CD4+ cells and CD49d-positive cells among total splenocytes (Figures S1A–S1F; data not shown). Notably, among CD4+ splenocytes,
Figure 2. SHARPIN and Inactive LFA-1 Colocalize in Uropods

(A and B) Expression of LFA-1 on isolated wild-type and Sharpincpdm thymocytes and total and CD4-positive splenocytes. Shown are (A) representative FACS plots and (B) the specific mean fluorescence intensities (MFI) ± SEM for CD11a.

(C) Immunostainings of cytospin preparations of resting human PBMC with SHARPIN and control antibodies. DAPI was used to visualize nuclear morphology. An arrowhead points to a representative lymphocyte. The scale bars represent 10 μm.

(D) Immunostainings of freshly isolated, CXCL12-stimulated human PBMC migrating on recombinant human ICAM-1 (5 μg/ml) for SHARPIN (a nonpolarized and polarized cell are shown).

(E and F) Immunostainings of GFP-SHARPIN-transfected, CXCL12-stimulated human PBMC migrating on ICAM for (E) CD44 and (F) talin.

(G–I) Immunostainings of freshly isolated, CXCL12-stimulated human PBMC migrating on ICAM-1 for SHARPIN and (G) CD11a (total), (H) extended LFA-1 (KIM127 epitope), and (I) activated LFA-1 (24 epitope).

(J) Quantitations of mean fluorescence intensities (MFI) of the indicated stainings along the cell axis (mean ± SEM [SEM in gray color]; n > 4–8 cells/staining; statistical comparisons between the 20 first frontal and 20 last posterior measurement points) are shown.

In (D)–(I), the white arrows point to the uropods and the bars are 5 μm. Data in (A) and (B) are from four to nine mice/genotype and in (C)–(I) representative of at least three independent experiments with different blood cell donors. The asterisk denotes p < 0.05, double asterisks denote p < 0.01, and triple asterisks denote p < 0.001 (two-tailed Student’s t-test). See also Figure S1.
the expression of αM/CD11b and CD49d was similar in both genotypes. Together, these data show that the lymphocyte phenotypes of wild-type and Sharpincpdm lymphocytes are relatively similar and that SHARPIN preferentially localizes to uropods in migrating lymphocytes and regulates uropod stability, adhesion to the substrate, and migration velocity both in total splenocytes and purified CD4+ T cells.

**SHARPIN Preferentially Colocalizes with Inactive LFA-1 in Uropods**

To analyze the possible role of SHARPIN in regulating LFA-1 activity, we used human cells, for which reporter antibodies for LFA-1 activity are available. In freshly isolated human peripheral blood mononuclear cells (PBMCs) and in CXCL12-stimulated PBMC binding to recombinant ICAM-1, stainings with specific SHARPIN antibodies (Figures S1G and S1H) showed SHARPIN to be evenly distributed in the cytoplasm of nonpolarized cells (Figures 2C and 2D). In contrast, in polarized cells (>100 cells analyzed) endogenous SHARPIN was always concentrated in, but not restricted to, the uropods (Figures 2D and S1I). GFP-SHARPIN transfed into PBMC also preferentially localized in CD44-positive uropods and was less abundant in the tail-negative leading edges (Figures 2E and 2F). Leukocytes migrating in a lymphoid tissue in vivo also showed enrichment of endogenous SHARPIN in the uropods (Figure S3J).

In human cells migrating on ICAM-1, LFA-1 was found both at the leading edge and in the uropod, and endogenous SHARPIN (as well as GFP-SHARPIN) and LFA-1 partially colocalized in the uropods (Figures 2G, S1K, and S1L). KIM127 and 24 are unique reporter monoclonal antibodies (mAbs), which specifically detect the extended, intermediate-affinity, and high-affinity forms of LFA-1, respectively (Dransfield and Hogg, 1989; Hogg et al., 2011; Robinson et al., 1992). On freshly isolated, migrating PBMC, the KIM127 and 24 signals concentrated to the leading edge and midcell zones, whereas SHARPIN mainly localized to the uropod (Figures 2H and 2I). Thus, our quantitative data (Figure 2J) show that SHARPIN is enriched in uropods together with inactive LFA-1 in contrast to the integrin activator talin and active LFA-1, which mainly localize to the leading edge and midcell zones.

**SHARPIN Interacts with LFA-1**

SHARPIN has been shown to physically interact with CD29 cell adhesion receptors in cancer cells (Rantala et al., 2011). To study whether SHARPIN can physically interact with leukocyte integrins, we cotransfected plasmids encoding αL lacking the cytoplasmic domains, bound to recombinant GST-SHARPIN, but not GST alone, in pull-down assays (Figures 3D and 3E). Far-western analyses confirmed this interaction (Figure 3F). The full-length cytoplasmic sequence of αL, but not of β2, and the conserved membrane proximal part of the αL-tail synthesized as biotinylated peptides bound to GFP-SHARPIN from cell lysates (Figure 3G). The cytoplasmic sequences of other leukocyte integrins αM and αD (αD was insoluble) also interacted with GFP-SHARPIN (Figure 3G). All these experiments clearly show that SHARPIN directly binds to the cytoplasmic domain of αL.

**SHARPIN Maintains LFA-1 in an Inactive Conformation and Regulates Lymphocyte Extravasation**

Direct interaction between SHARPIN and LFA-1 and the colocalization of inactive LFA-1 and SHARPIN in the uropods led us to study whether SHARPIN could be involved in LFA-1 inactivation. Knockdown of SHARPIN in human PBMC (on average 50%–70%) increased the adhesion of these cells to human recombinant ICAM-1, improved their migration on low ICAM-1 concentration, and inhibited their migration on high ICAM-1 concentration (Figures 4A and 4B). Conversely, overexpression of SHARPIN significantly reduced the expression of the LFA-1 activation epitopes KIM127 and 24 on cultured, CXCL12-stimulated PBMC in fluorescence-activated cell sorting (FACS) analyses (Figures 4C and S3A). Moreover, transiently expressed human LFA-1 was more active in Sharpincpdm mouse embryonic fibroblasts (MEFs) than in wild-type MEFs (Figures 4D and S3B). These functional data show that SHARPIN inhibits LFA-1.

To study the role of SHARPIN in lymphocyte migration in vivo, we performed competitive homing assays, in which the ability of lymphocytes to move from the blood through the vessel wall into the tissue is measured. Splenocytes from wild-type and Sharpincpdm mice were isolated, labeled with two different intensities of a fluorescent dye (carboxyfluorescein succinimidyl ester [CFSE]) and injected intravenously into wild-type recipients. After a 2 hr recirculation period, Sharpincpdm lymphocytes (both total splenocytes and CD4+ lymphocytes) homed to peripheral (PLN) and mesenteric (MLN) lymph nodes with about half the efficiency of their wild-type counterparts (seven mice per group; Figures 4E and 4F). In an independent experiment, the reduced lymph node homing of Sharpincpdm splenocytes and CD4+ T cells was confirmed and we observed that, instead, Sharpincpdm cells accumulated more in the spleen than wild-type cells (Figure S3C). Also, in microscopic analyses, fewer Sharpincpdm lymphocytes accumulated in PLN parenchyma than wild-type cells 30 min after intravenous transfer (Figure 4G). Thus, absence of SHARPIN impairs lymphocyte homing to lymph nodes.

The function of SHARPIN in lymphocyte transmigration was studied using time-lapse microscopy in vitro, where both splenocytes and CD4+ lymphocytes were transfected with GFP-SHARPIN and CD44-GFP. After adhesion, control small interfering RNA (siRNA)-silenced human peripheral blood mononuclear cells (PBMCs) were transfected with CXCL12 and stimulated with CXCL12 for 2 hr, and the majority of cells swiftly moved onward from the transmigration site (Figure 4H; Movie S3).
SHARPIN-silenced cells transmigrated with similar kinetics, but thereafter they migrated less persistently away from the transmigration sites and often had to make repetitive efforts to leave the transmigration spot below the endothelium (Figure 4I; Movie S3).

SHARPIN Rescues Migration and Uropod Detachment Defects of SHARPIN-Deficient Cells

Sharpincpdm splenocytes expressing GFP-SHARPIN bound 60% less to ICAM-1 (5 μg/ml) than Sharpincpdm splenocytes expressing GFP only (Figure 4J), showing that the increased adhesion of Sharpincpdm cells on ICAM-1 was SHARPIN-dependent. Binding of Sharpincpdm splenocytes to a non-integrin-dependent ligand (poly-L-lysine) was not affected by SHARPIN.

The migration velocity of GFP-expressing Sharpincpdm lymphocytes on ICAM-1 (5 μg/ml) was significantly higher than that of GFP-expressing wild-type cells (Figure 4K). Importantly, overexpression of GFP-SHARPIN in Sharpincpdm cells reduced the migration velocity significantly by 60% compared to GFP only. In fact, wild-type and Sharpincpdm cells overexpressing SHARPIN had comparable migration velocities. Moreover, expression of GFP-SHARPIN, but not GFP alone, in Sharpincpdm cells decreased the number of cells with uropods (Figure 4L).

Thus, SHARPIN is causally involved in regulating uropod formation, polarization, and lymphocyte motility on ICAM-1.

DISCUSSION

This study identifies a function for SHARPIN in regulating cell polarization and uropod detachment in migrating lymphocytes. We also describe SHARPIN as the first endogenous molecule capable of inhibiting LFA-1 by binding directly to the integrin α-tail. These data show that the inactive LFA-1 conformation is not merely a passive default state in the leukocytes but
is actively maintained through adjustable intracellular protein interactions.

Increased LFA-1 activation epitopes associated with lack of SHARPIN expression and diminished LFA-1 activation with increased SHARPIN expression. Because SHARPIN did not alter LFA-1 expression levels, these data directly implicate SHARPIN in regulation of LFA-1 activity. Because there is always a dynamic balance between active and inactive LFA-1 on the cell membrane, SHARPIN could help to maintain LFA-1 in an inactive conformation by preventing activation and/or by deactivating the active conformation. Thus, in nonadherent and freshly adherent cells, which do not have uropods and which display even active conformation by preventing activation and/or by deactivating the membrane, SHARPIN could help to maintain LFA-1 in an inactive conformation. SHARPIN may function in regulating general LFA-1 adhesiveness and activation.

In migrating lymphocytes, adhesive cell-substrate contacts need to be disengaged at the trailing edge to allow net forward movement of the cell (Smith et al., 2005). We showed that in migrating cells SHARPIN preferentially redistributes to uropods, to which inactive LFA-1 is recruited (Morin et al., 2008; Smith et al., 2005). The effects of SHARPIN on lymphocyte migration were dependent on the ligand concentration. Increased LFA-1 activation in the absence of SHARPIN enhanced cell migration on low ICAM-1 concentration and inhibited migration on high ICAM-1 concentration and in transmigration assays. Similarly, constitutively active LFA-1 mutant T cells (lacking the cytoplasmic domain) adhere better to ICAM-1 but show impaired transendothelial migration in vitro and migrate worse to tissues in vivo than wild-type cells (Lu and Springer, 1997; Semmrich et al., 2005). A small-molecule agonist of LFA-1 also enhances ligand binding and inhibits transendothelial migration of lymphocytes accompanied by uropod elongation and impaired de-adhesion (Yang et al., 2006). Also, T cells carrying a constitutively active mutant (an engineered point mutation in the extracellular domain) adhere better to ICAM-1 and yet home worse than wild-type cells to PLN and MLN in vivo (Park et al., 2010). These data strongly implicate the role of LFA-1 activity regulation also in in vivo homing, although the contribution of slight changes in the LFA-1 expression levels was not formally excluded. In fact, LFA-1-dependent uropod elongation has very recently been proposed to be a final common step during transendothelial migration (Hyun et al., 2012). Therefore, a release mechanism is needed before the cell can migrate further into the tissue, and we postulate that SHARPIN, which is enriched in the uropod of extravasating leukocytes, facilitates homing, and enhances cell movement after transendothelial migration, could play an important role in this process.

The results that SHARPIN-negative cells showed impaired short-term (30 min–2 hr) homing to lymph nodes and yet SHARPIN-deficient mice suffer from chronic inflammation may have several explanations. The chronic inflammatory phenotype develops during a much longer time period (the first 4–6 weeks of postnatal life; HogenEsch et al., 1993), during which many other LFA-1 mediated inflammatory functions apart from the initial entry may become relevant. For instance, LFA-1–ICAM-1 interaction contributes to T cell costimulation (Wölfing and Davis, 1998) and lymphocyte exit from the lymph nodes into lymphatic vasculature (Reichardt et al., 2013), and therefore, deregulated LFA-1 activity in Sharpincpdm cells may modulate these processes. Finally, in vivo SHARPIN-deficient cells localized better than wild-type cells to spleen (which is one of the affected organs in Sharpincpdm mice), implicating that the contribution of LFA-1 activity regulation may vary in different organs.

Activation of LFA is essential for its function (Abram and Lowell, 2009; Gahmberg et al., 2009; Hogg et al., 2011; Kinashi, 2007). LFA-1 is normally found in an inactive (i.e., incompetent for ligand binding) form on leukocytes, and only after receiving activation signals, does it become functionally competent. Critical for the activation is the interaction of the cytoplasmic domain of the β chain with talin and kindlins, which leads to conformational changes of the extracellular domains in the integrin heterodimer (Moser et al., 2009; Shattil et al., 2010). LFA-1 activation can be indirectly inhibited through certain signaling molecules, such as Cdc42, PIP5K1γ90, cytokine growth differentiation factor-15, and E3 ubiquitin ligase Cbl-b, which interfere with the upstream activation signals (Bolomini-Vittori et al., 2009; Hogg et al., 2011; Kinashi, 2007; Wernimont et al., 2010; Zhang et al., 2003). In contrast, SHARPIN directly binds to the cytosolic membrane proximal sequence of the α-tail of LFA-1. Certain artificial deletions of the αL cytoplasmic tail increase LFA-1 activity and cell adhesion to ICAM-1 (Lu and Springer, 1997; Semmrich et al., 2005). These mutants are predicted to be unable to bind SHARPIN, which could explain why these mutants are constitutively active.

Delineation of multiple functions and the physiological role of SHARPIN remains an important area of future investigation. It will be critical to determine whether SHARPIN can simultaneously function as a component of the LUBAC complex and an inhibitor of integrins, possibly implicating a role for linear ubiquitination/NF-κB signaling in the regulation of integrin signaling, or whether these two binding modes are mutually exclusive. Moreover, we have shown that binding of SHARPIN to the conserved segment of the α-cytoplasmic tails of collagen and fibronectin-binding z2β1- and z2β1-integrins in cancer cells prevents recruitment of the integrin activators talin and kindlin with the β1-tail via a yet-unknown mechanism (Rantala et al., 2011). Whether similar mechanisms operate in inhibition of LFA-1 by SHARPIN remains to be determined, but also additional mechanisms could be involved. SHARPIN thus inhibits both β1- and β2-integrins, although the activity regulation of β1-integrins in adherent epithelial and mesenchymal cells is fundamentally different from that of β2-integrins in professionally motile leukocytes. Activity regulation of β1-integrins is modulatory, because these extracellular matrix receptors are always at least partially active and strongly coupled to actin. In sharp contrast, activation of β2-integrins needs to be fully switchable from inactive to active within seconds to allow extravasation of blood-borne leukocytes. In addition, many of the integrin activators are specific for β2-integrins over β1-integrins (e.g., the guanosine triphosphatase Rap1 regulating LFA-1 vesicle traffic, RAPL regulating LFA-1 transport, and adaptor 14-3-3 binding to phosphorylated β2-integrin), and the Rap1-RAPL-dependent LFA-1 activation involves binding to the alpha-subunit cytoplasmic region of LFA-1 immediately adjacent to the SHARPIN-binding site (Hogg et al., 2011; Katagiri et al., 2003). This suggests that SHARPIN-mediated LFA-1 inactivation may...
Figure 4. Sharpin Deactivates LFA-1, Improves Lymphocyte Extravasation, and Re-expression of SHARPIN Rescues the Uropod and Migration Defects of SHARPIN-Deficient Cells

(A and B) Adhesion (A) and migration (B) of human PBMC transfected with SHARPIN siRNA or control siRNA on recombinant human ICAM-1 and the efficacy of knockdown on SHARPIN protein levels.

(C) FACS analyses of the reporter mAb 24 and KIM127 cell surface binding to GFP-SHARPIN- and control (GFP only)-expressing, CXCL12-stimulated human PBMC. The results are normalized against total CD11a expression.

(D) Cell-surface expression of 24 reporter epitope (normalized to total αL expression, left panel) and total αL expression (MFI, right panel) on wild-type and Sharpincpdm MEFs expressing human LFA-1 was determined using FACS (a representative experiment).

(legend continued on next page)
involve mechanisms that do not play a role in the regulation of β1-integrins. However, this remains to be investigated in detail. The specific physiological contribution of SHARPIN-mediated NF-κB activation (via LUBAC) and integrin inactivation in different lymphoid and nonlymphoid tissues and at different time points also needs to be determined in the future using in vivo imaging, specific inhibitors, and cell-type-specific conditional knockouts.

In conclusion, we have shown that SHARPIN preferentially localizes to uropods in migrating lymphocytes, directly binds to the cytoplasmic tail of αL-integrin, and keeps LFA-1 inactive in these cells. Thereby, SHARPIN regulates uropod detachment and locomotion and transendothelial migration of inflammatory cells. Our findings challenge the prevailing dogma that the inactive LFA-1 is the passive default form of the molecule by showing that active interaction with endogenous SHARPIN is required to maintain LFA-1 in the nonactivated state.

EXPERIMENTAL PROCEDURES

Mice, Cells, and Transfections

Spontaneously SHARPIN-deficient C57BL/KaLwRij-SHARPIN<sup>Sharpincpdm</sup>/RijSunJ (abbreviated Sharpin<sup>cpdm</sup>) mice (HogenEsch et al., 1993; Seymour et al., 2007) were maintained using heterozygote breedings. Sex-matched littermate wild-type and Sharpin<sup>cpdm</sup> animals (6–8 weeks) were used in all experiments. The animal studies were approved by the Animal Experiment Board in Finland. Mouse splenocytes and thymocytes were isolated using mechanical teasing and CD4+ T cells purified by negative selections. Human PBMC and mouse lymphocytes were transfected with plasmids and siRNAs using human and mouse T cell nucleofection kits (Amaxa).

Adhesion and Migration Assays and Uropod Analyses

Cells were allowed to adhere to precoated wells (5 μg/ml ICAM-1 or poly-L-lysine), washed, fixed, stained with propidium iodide, and quantified with NIH ImageJ software. The extended uropods (uropod length >33% of cell body diameter) and the duration of uropod attachment were scored from the time-lapse videos. The polarization index of cells was calculated as the ratio of x to y, where x is the longest distance across cells (from head to tail) and y is the greatest width perpendicular to x.

Human and mouse leukocytes adhering or migrating on ICAM-1 were stained for immunofluorescence using earlier-described protocols (Rantaia et al., 2011). Migrating cells were stained with KIM127 and 24 using a 80 s exposure of live cells before fixation (Smith et al., 2005). For FACS analysis, cells were labeled using indirect or direct staining techniques and analyzed using FACSciCalibur with CellQuest software (BD Biosciences).

Immunoblottings, Immunoprecipitations, Pull-Downs, and Far-Western Assays

Immunoblotting and immunoprecipitations were done as described (Mattila et al., 2005). For the pull-down analysis, the cells were lysed or the recombinant protein diluted in a 2% β-oxidiglycerol-containing lysis buffer, incubated with 2.5 μM biotinylated integrin-peptides bound to streptavidin-Sepharose beads, washed, and immunoblotted. For far-western assays, purified proteins were spotted on nitrocellulose membranes, incubated with different GST-SHARPIN proteins in blocking buffer, washed, and detected with GST antibody.

Statistical Analysis

The numerical data are presented as mean ± SEM. Each individual experiment used cells from different persons or different mice. All statistical analyses were performed with two-tailed Student’s t test. p < 0.05 was considered significant.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, three movies, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2013.10.011.

ACKNOWLEDGMENTS

We thank Ms. Petra Laasola, Laura Lahtinen, Jenni Sivonen, Riikka Sjóroos, Etta-Lisa Väänänen, Kathleen Silva, and Sari Mäki for expert technical help. Dr. Hans–Jürgen Kreienkamp is acknowledged for providing mice. The study was supported by the grants from the European Research Council, Academy of Finland, Sigrid Juselius Foundation, Cancer Research UK, the Wellcome Trust, and by the NIH AR49288 grant. J.P. has been funded by the Finnish Cancer Institute and the Instrumentarium Research Foundation.

Received: April 19, 2013
Revised: July 8, 2013
Accepted: October 6, 2013
Published: November 7, 2013

REFERENCES


(E) Representative FACS plots of the input population and transferred cells isolated from mesenteric lymph nodes of wild-type recipient mice in the homing experiments after 2 hr. Wild-type (indicated by blue arrow) and Sharpin<sup>cpdm</sup> (indicated by red arrow) donor splenocytes are CFSE dim and bright, respectively, and the cells were contained with Alexa 647-labeled anti-CD4.

(F) Percentages of wild-type and Sharpin<sup>cpdm</sup> CD4+ positive and total lymphocytes in the mesenteric (MLN) and peripheral (PLN) lymph nodes of wild-type recipient mice after a 2 hr recirculation period (n = 7 mice/genotype).

(G) Microscopic analyses of homing of wild-type (red) and Sharpin<sup>cpdm</sup> (green) cells to PLN after a 30 min recirculation. MECA-79-positive high-endothelial venules are shown in gray. A representative micrograph and pooled data (n = 7 recipient mice; 187 homed wild-type cells) are shown. The scale bar represents 50 μm.

(H) and (I) Transmigration of human PBMC transfected with SHARPIN siRNA or control siRNA through an endothelial monolayer in in vitro flow assay. (H) Expression of SHARPIN in a PBMC transmigrating through CD31+ endothelial monolayer (endothelial borders are shown by a dashed line, and the arrow indicates the leukocyte uropod and the arrowhead the PBMC cell body below the endothelium). (I) Net displacement of PBMC after transmigration (n = 40 control siRNA and n = 45 SHARPIN siRNA transfected cells from three independent experiments with different blood and endothelial cell donors). See also Movie S3.

(J) Adhesion assays determining the binding of wild-type and Sharpin<sup>cpdm</sup> splenocytes expressing GFP-SHARPIN or GFP alone to ICAM-1 and poly-L-lysine (PLL, a nonintegrin-binding ligand).

(K) Migration velocity of wild-type and Sharpin<sup>cpdm</sup> splenocytes expressing GFP-SHARPIN or GFP alone on ICAM-1.

(L) Uropod formation on Sharpin<sup>cpdm</sup> cells expressing SHARPIN-GFP or GFP alone after CXCL12 stimulation and migration on ICAM-1 (50 μg/ml). Data are the mean ± SEM of three (A and I), two (B, G, and J–L), and two to five (C) independent experiments. The asterisk denotes p < 0.05, double asterisks denote p < 0.01, and triple asterisks denote p < 0.001 (two-tailed Student’s t test). See also Figure S3.


